We are live on ! Find out more
TG

TRV GP Portfolio holdings

AUM $18.9M
1-Year Est. Return 541.67%
This Fund
S&P 500
This Quarter Est. Return
+0.13%
1 Year Est. Return
+541.67%
3 Year Est. Return
+3,178.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$221M
AUM Growth
–
Cap. Flow
+$210M
Cap. Flow %
95.09%
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
–
Reduced
–
Closed
–

Top Buys

1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$105M
2
CTMX icon
CytomX Therapeutics
CTMX
+$68.8M
3
KALA icon
KALA BIO
KALA
+$31M
4
CARM
Carisma Therapeutics
CARM
+$4.5M
5
LRMR icon
Larimar Therapeutics
LRMR
+$790K

Top Sells

No sells this quarter

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
1
Rhythm Pharmaceuticals
RYTM
$7.28B
$116M 52.29%
+3,981,437
New +$105M
CTMX icon
2
CytomX Therapeutics
CTMX
$798M
$70.1M 31.68%
+3,320,348
New +$68.8M
KALA icon
3
KALA BIO
KALA
$15.7M
$30.6M 13.82%
+662
New +$31M
CARM
4
DELISTED
Carisma Therapeutics
CARM
$3.92M 1.77%
+242,080
New +$4.5M
LRMR icon
5
Larimar Therapeutics
LRMR
$381M
$972K 0.44%
+17,531
New +$790K

Similar funds

KA
KSL Advisors Denver, Colorado $16.1M AUM
FRGX
First Reserve GP XII Stamford, Connecticut $3.16M AUM 24.66% 1-Year Est. Return
DHRFI
DCM Hybrid RMB Fund International Menlo Park, California $35.3M AUM
SA
Silversage Advisors Irvine, California $2.41M AUM 46.55% 1-Year Est. Return
YECIP
YT Extraction Co Investment Partners New York $1.73M AUM
FFIM
Founders Fund II Management San Francisco, California $1.32M AUM
ES
Equitec Specialists Chicago, Illinois $708K AUM 25.27% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

TRV GP's Q4 2017 Portfolio in Review

Q4 2017 is the first quarter with a 13F filing on record for TRV GP, which disclosed 5 positions worth $221M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Rhythm Pharmaceuticals: 3,981,437 shares worth $116M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • TRV GP's largest Q4 2017 buy was Rhythm Pharmaceuticals: 3,981,437 shares worth $116M.
  • TRV GP's ten largest holdings make up 100% of its $221M portfolio in Q4 2017.
  • TRV GP disclosed 5 positions in Q4 2017, its first 13F filing on record.

Based on TRV GP's 13F filing for Q4 2017, filed 13 Feb 2018.